Overview

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

Status:
Withdrawn
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Timolol 0.5% Gel Forming Solution is safe and effective in promoting wound healing of infantile ulcerated hemangiomas compared with standard conservative management with topical antibiotic.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborator:
Society for Pediatric Dermatology
Treatments:
Mupirocin
Pharmaceutical Solutions
Timolol